BioSpace News Archive

Harpreet Singh is the chief medical officer of Precision for Medicine, a global leader in biomarker-driven clinical research and development. Previously, Dr. Singh was director, Division of Oncology 2, Office of Oncologic Diseases, a division that regulated drugs and biologics for the treatment of thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors.

Last week, Eli Lilly also responded to the President’s tariff warnings by investing $27 billion to construct four manufacturing facilities across the U.S. in five years.

Delphia launched in May 2024 with the goal of forcing malignant cells to overactivate and die.

Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.

TNKase is the first stroke drug to win FDA approval in nearly three decades.

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the drug in gastric and gastroesophageal cancers as BeiGene also pushes forward a pipeline of novel cancer therapies.

Less than two months after two FDA-related setbacks, Atara Biotherapeutics is again cutting its workforce in half. This time, it’s also hitting pause on two CAR T programs, including one affected by an FDA clinical hold in January.

In the second podcast in a special series focused on BioSpace’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Kevin Marks, CEO of Delphia Therapeutics.

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers.